Task 59: Clinical Case Analysis

1. Preliminary Diagnosis

• Pulmonary emphysema (secondary, hyperinflation).
• Peribronchial and interstitial changes (pneumosclerosis).
• Possible pulmonary hypertension with early cor pulmonale, or a separate cardiac cause (see the inconsistencies below).
• Arterial hypertension, grade 1 by BP 140/90, needing repeat measurement.

2. Justification of Diagnosis

Chief complaints

• Exertional dyspnea and suffocation: exercise-induced bronchoconstriction, from airway heat and water loss and mediator release.
• Nocturnal attacks: classic for asthma, due to circadian airway tone (vagal, low cortisol) and increased airway inflammation at night.
• Chest tightness: bronchospasm and air trapping.
• Salbutamol relief 3-4 times a day: a strong clue to reversible obstruction. Daily reliever use also shows poor control.

History of present illness

• Onset after severe pneumonia 11 years ago. Post-infectious airway hyperresponsiveness is well described.
• Attacks are triggered by exertion and colds, typical asthma triggers (viral infection, exercise).
• Recurrent, episodic, reversible course, unlike the steady progression of COPD.
• Control assessment (GINA): daytime symptoms more than 2 times a week, night waking, reliever need more than 2 times a week, and activity limitation. All four are present, so asthma is uncontrolled.
• No smoking, so COPD is less likely. The reported absence of allergy does not exclude asthma, because non-allergic (non-atopic) asthma is common in adults.

Physical examination

• Bandbox (vesiculotympanitic) percussion note: increased air content from hyperinflation and emphysema.
• Harsh breathing, diffuse dry rales, wheeze on forced exhalation: diffuse narrowing of small and medium airways with prolonged expiration.
• Respiratory rate 18/min and satisfactory condition: the patient is between attacks, not in an acute exacerbation. Wheeze may be absent in a patient who is not symptomatic at the time of examination.
• Cyanosis, edema and hepatomegaly are absent, so there is no clinical sign of decompensation.

Laboratory data

• WBC 9.5 × 10⁹/L (4-9): at the upper limit of normal, with no left shift or infection.
• Eosinophils 5% (ref 0.5-5%): about 475 cells/µL absolute. This is borderline-high, consistent with type 2 inflammation (≥300/µL).
• Sputum eosinophils 10-12/HPF: supports eosinophilic airway inflammation. Normal sputum has almost none.
• Mucoid, odorless sputum with 5-6 WBC/HPF: no purulent infection. This argues against bronchiectasis and a lung abscess.
• M. tuberculosis negative ×3: reduces the likelihood of TB, though it does not fully exclude it.
• Relative lymphopenia (13%; ref 19-37%): nonspecific.
• ESR 19 mm/h: upper normal, no marked systemic inflammation.
• Hb "12.6 g/L": likely a typo for 126 g/L (12.6 g/dL). This is low-normal (ref 120-140 g/L), with no anemia. RBC 3.9 × 10¹²/L is normal (3.7-4.7). The absence of secondary polycythemia suggests no chronic severe hypoxemia.
• Bilirubin 5.3 µmol/L (3.4-20.5), protein 82 g/L (65-85), urea 4.7 mmol/L (2.5-8.3): normal.
• Urinalysis: normal. Protein-negative, specific gravity 1028 is normal.

Chest X-ray

• Hyperlucent lung fields: hyperinflation and air trapping.
• Flat, low diaphragm: air trapping and increased lung volume.
• Reticular opacities: peribronchial or interstitial fibrosis (pneumosclerosis) from past pneumonia or chronic inflammation. They may also point to other interstitial disease.
• Enlarged, denser lung roots: pulmonary arterial dilatation (possible pulmonary hypertension), peribronchial thickening, or hilar lymphadenopathy.
• Enlarged cardiac shadow: see below.

Pathophysiology

• Bronchial hyperresponsiveness.
• Bronchospasm.
• Mucosal edema and mucus hypersecretion.
• Eventually remodeling (subepithelial fibrosis, smooth muscle hypertrophy).

Inconsistencies and findings suggesting other pathology

1. Enlarged heart on X-ray vs. unchanged heart borders on examination. With emphysema, the heart is usually narrow ("drop-shaped") because of the low diaphragm. An enlarged shadow therefore needs explanation. The possibilities are right ventricular enlargement (cor pulmonale), left ventricular hypertrophy from hypertension, cardiomyopathy or pericardial effusion, or a technical artifact (projection or inspiration). Echocardiography is needed.
2. Muffled heart tones and BP 140/90 support a cardiac contribution.
3. Reticular opacities and enlarged roots are not typical for uncomplicated asthma. They need HRCT to exclude bronchiectasis, interstitial disease, sarcoidosis or ABPA.
4. "No allergy" vs. eosinophilia: suggests non-atopic eosinophilic asthma, but allergy testing should still be done.

3. Plan for Additional Investigations

• Spirometry (FEV1, FVC, FEV1/FVC): confirms obstruction and its severity. Expect FEV1/FVC below 0.70 (or below the lower limit of normal) and reduced FEV1. It also gives a baseline for follow-up.
• Bronchodilator reversibility test (400 µg salbutamol): a post-bronchodilator FEV1 increase of ≥12% and ≥200 mL confirms variable airflow limitation. Reversibility may be incomplete if remodeling is present.
• PEF monitoring for 2 weeks: diurnal variability >10% supports asthma and helps to assess control.
• FeNO: expected to be elevated (≥20-25 ppb) in eosinophilic asthma. It supports the diagnosis and helps predict ICS response.
• Methacholine challenge: only if spirometry is normal or equivocal.

• Total IgE and specific IgE (or skin prick tests): to look for atopy. A high total IgE with Aspergillus-specific IgE would raise ABPA.
• Repeat blood eosinophil count: guides biologic choice if needed.

• HRCT chest: to clarify reticular opacities, enlarged hila and bronchiectasis, and to define emphysema.
• ECG: right axis deviation, P pulmonale or RVH would suggest cor pulmonale. LVH would suggest a hypertensive heart.
• Echocardiography: chamber size, RV function, estimated pulmonary artery pressure and LV function. This addresses the enlarged cardiac shadow directly.
• Pulse oximetry, and arterial blood gas only if saturation is low or in a severe attack: assesses hypoxemia and hypercapnia.
• BNP/NT-proBNP: if heart failure is suspected, since it helps to exclude cardiac asthma.
• Body plethysmography and DLCO: to quantify hyperinflation (RV/TLC) and reduced diffusion in emphysema or interstitial disease.
• Alpha-1 antitrypsin level: emphysema at a relatively young age.
• Additional sputum testing: only if the sputum becomes purulent or TB remains suspected, using a Xpert/culture test.

4. Differential Diagnosis

• For: hyperinflation, obstruction, wheeze.
• Against: non-smoker, no chronic productive cough, onset at 34 (after pneumonia), episodic attacks with night symptoms, eosinophilia, and marked reversibility on salbutamol.
• Distinguishing tests: spirometry (post-bronchodilator FEV1/FVC persistently <0.70 with little reversibility), DLCO, HRCT. Asthma-COPD overlap is possible with long-standing disease.

• For: post-infectious course, rales.
• Against: no chronic daily cough with sputum for 3 months over 2 consecutive years, and no smoking or occupational dust exposure.
• Test: clinical history and spirometry.

• For: onset after severe pneumonia, reticular changes, enlarged roots.
• Against: sputum is mucoid and scant, with no purulent daily sputum, hemoptysis, clubbing or recurrent infections.
• Test: HRCT.

• For: nocturnal dyspnea, enlarged cardiac shadow, muffled heart tones, BP 140/90.
• Against: no orthopnea, edema, hepatomegaly or basal crackles, and symptoms are relieved by salbutamol.
• Tests: BNP, ECG, echocardiography. This remains the main differential to exclude and may coexist.

• For: X-ray changes, enlarged roots.
• Against: negative sputum ×3, no fever, weight loss or night sweats, normal ESR and no lymphopenia.
• Tests: HRCT, Xpert MTB/RIF, Mantoux or IGRA.

• ABPA: eosinophilia, post-infection course, hilar changes. Test with total IgE and Aspergillus IgE, and look for central bronchiectasis on HRCT.
• EGPA: asthma with eosinophilia. No sinusitis, neuropathy or vasculitic features here, but ANCA could be checked if these develop.
• Post-infectious bronchiolitis obliterans (Swyer-James): hyperlucency after severe infection, typically unilateral. Features are air trapping on expiratory HRCT and fixed obstruction.
• Sarcoidosis and interstitial lung disease: hilar enlargement and reticular opacities. Test with HRCT, DLCO and biopsy if needed.
• Vocal cord dysfunction and GERD-related cough: mimic or worsen asthma. Consider laryngoscopy and a PPI trial.

Task 59: Clinical Case Analysis

1. Preliminary Diagnosis

• Pulmonary emphysema (secondary, hyperinflation).
• Peribronchial and interstitial changes (pneumosclerosis).
• Possible pulmonary hypertension with early cor pulmonale, or a separate cardiac cause (see the inconsistencies below).
• Arterial hypertension, grade 1 by BP 140/90, needing repeat measurement.

2. Justification of Diagnosis

Chief complaints

• Exertional dyspnea and suffocation: exercise-induced bronchoconstriction, from airway heat and water loss and mediator release.
• Nocturnal attacks: classic for asthma, due to circadian airway tone (vagal, low cortisol) and increased airway inflammation at night.
• Chest tightness: bronchospasm and air trapping.
• Salbutamol relief 3-4 times a day: a strong clue to reversible obstruction. Daily reliever use also shows poor control.

History of present illness

• Onset after severe pneumonia 11 years ago. Post-infectious airway hyperresponsiveness is well described.
• Attacks are triggered by exertion and colds, typical asthma triggers (viral infection, exercise).
• Recurrent, episodic, reversible course, unlike the steady progression of COPD.
• Control assessment (GINA): daytime symptoms more than 2 times a week, night waking, reliever need more than 2 times a week, and activity limitation. All four are present, so asthma is uncontrolled.
• No smoking, so COPD is less likely. The reported absence of allergy does not exclude asthma, because non-allergic (non-atopic) asthma is common in adults.

Physical examination

• Bandbox (vesiculotympanitic) percussion note: increased air content from hyperinflation and emphysema.
• Harsh breathing, diffuse dry rales, wheeze on forced exhalation: diffuse narrowing of small and medium airways with prolonged expiration.
• Respiratory rate 18/min and satisfactory condition: the patient is between attacks, not in an acute exacerbation. Wheeze may be absent in a patient who is not symptomatic at the time of examination.
• Cyanosis, edema and hepatomegaly are absent, so there is no clinical sign of decompensation.

Laboratory data

• WBC 9.5 × 10⁹/L (4-9): at the upper limit of normal, with no left shift or infection.
• Eosinophils 5% (ref 0.5-5%): about 475 cells/µL absolute. This is borderline-high, consistent with type 2 inflammation (≥300/µL).
• Sputum eosinophils 10-12/HPF: supports eosinophilic airway inflammation. Normal sputum has almost none.
• Mucoid, odorless sputum with 5-6 WBC/HPF: no purulent infection. This argues against bronchiectasis and a lung abscess.
• M. tuberculosis negative ×3: reduces the likelihood of TB, though it does not fully exclude it.
• Relative lymphopenia (13%; ref 19-37%): nonspecific.
• ESR 19 mm/h: upper normal, no marked systemic inflammation.
• Hb "12.6 g/L": likely a typo for 126 g/L (12.6 g/dL). This is low-normal (ref 120-140 g/L), with no anemia. RBC 3.9 × 10¹²/L is normal (3.7-4.7). The absence of secondary polycythemia suggests no chronic severe hypoxemia.
• Bilirubin 5.3 µmol/L (3.4-20.5), protein 82 g/L (65-85), urea 4.7 mmol/L (2.5-8.3): normal.
• Urinalysis: normal. Protein-negative, specific gravity 1028 is normal.

Chest X-ray

• Hyperlucent lung fields: hyperinflation and air trapping.
• Flat, low diaphragm: air trapping and increased lung volume.
• Reticular opacities: peribronchial or interstitial fibrosis (pneumosclerosis) from past pneumonia or chronic inflammation. They may also point to other interstitial disease.
• Enlarged, denser lung roots: pulmonary arterial dilatation (possible pulmonary hypertension), peribronchial thickening, or hilar lymphadenopathy.
• Enlarged cardiac shadow: see below.

Pathophysiology

• Bronchial hyperresponsiveness.
• Bronchospasm.
• Mucosal edema and mucus hypersecretion.
• Eventually remodeling (subepithelial fibrosis, smooth muscle hypertrophy).

Inconsistencies and findings suggesting other pathology

1. Enlarged heart on X-ray vs. unchanged heart borders on examination. With emphysema, the heart is usually narrow ("drop-shaped") because of the low diaphragm. An enlarged shadow therefore needs explanation. The possibilities are right ventricular enlargement (cor pulmonale), left ventricular hypertrophy from hypertension, cardiomyopathy or pericardial effusion, or a technical artifact (projection or inspiration). Echocardiography is needed.
2. Muffled heart tones and BP 140/90 support a cardiac contribution.
3. Reticular opacities and enlarged roots are not typical for uncomplicated asthma. They need HRCT to exclude bronchiectasis, interstitial disease, sarcoidosis or ABPA.
4. "No allergy" vs. eosinophilia: suggests non-atopic eosinophilic asthma, but allergy testing should still be done.

3. Plan for Additional Investigations

• Spirometry (FEV1, FVC, FEV1/FVC): confirms obstruction and its severity. Expect FEV1/FVC below 0.70 (or below the lower limit of normal) and reduced FEV1. It also gives a baseline for follow-up.
• Bronchodilator reversibility test (400 µg salbutamol): a post-bronchodilator FEV1 increase of ≥12% and ≥200 mL confirms variable airflow limitation. Reversibility may be incomplete if remodeling is present.
• PEF monitoring for 2 weeks: diurnal variability >10% supports asthma and helps to assess control.
• FeNO: expected to be elevated (≥20-25 ppb) in eosinophilic asthma. It supports the diagnosis and helps predict ICS response.
• Methacholine challenge: only if spirometry is normal or equivocal.

• Total IgE and specific IgE (or skin prick tests): to look for atopy. A high total IgE with Aspergillus-specific IgE would raise ABPA.
• Repeat blood eosinophil count: guides biologic choice if needed.

• HRCT chest: to clarify reticular opacities, enlarged hila and bronchiectasis, and to define emphysema.
• ECG: right axis deviation, P pulmonale or RVH would suggest cor pulmonale. LVH would suggest a hypertensive heart.
• Echocardiography: chamber size, RV function, estimated pulmonary artery pressure and LV function. This addresses the enlarged cardiac shadow directly.
• Pulse oximetry, and arterial blood gas only if saturation is low or in a severe attack: assesses hypoxemia and hypercapnia.
• BNP/NT-proBNP: if heart failure is suspected, since it helps to exclude cardiac asthma.
• Body plethysmography and DLCO: to quantify hyperinflation (RV/TLC) and reduced diffusion in emphysema or interstitial disease.
• Alpha-1 antitrypsin level: emphysema at a relatively young age.
• Additional sputum testing: only if the sputum becomes purulent or TB remains suspected, using a Xpert/culture test.

4. Differential Diagnosis

• For: hyperinflation, obstruction, wheeze.
• Against: non-smoker, no chronic productive cough, onset at 34 (after pneumonia), episodic attacks with night symptoms, eosinophilia, and marked reversibility on salbutamol.
• Distinguishing tests: spirometry (post-bronchodilator FEV1/FVC persistently <0.70 with little reversibility), DLCO, HRCT. Asthma-COPD overlap is possible with long-standing disease.

• For: post-infectious course, rales.
• Against: no chronic daily cough with sputum for 3 months over 2 consecutive years, and no smoking or occupational dust exposure.
• Test: clinical history and spirometry.

• For: onset after severe pneumonia, reticular changes, enlarged roots.
• Against: sputum is mucoid and scant, with no purulent daily sputum, hemoptysis, clubbing or recurrent infections.
• Test: HRCT.

• For: nocturnal dyspnea, enlarged cardiac shadow, muffled heart tones, BP 140/90.
• Against: no orthopnea, edema, hepatomegaly or basal crackles, and symptoms are relieved by salbutamol.
• Tests: BNP, ECG, echocardiography. This remains the main differential to exclude and may coexist.

• For: X-ray changes, enlarged roots.
• Against: negative sputum ×3, no fever, weight loss or night sweats, normal ESR and no lymphopenia.
• Tests: HRCT, Xpert MTB/RIF, Mantoux or IGRA.

• ABPA: eosinophilia, post-infection course, hilar changes. Test with total IgE and Aspergillus IgE, and look for central bronchiectasis on HRCT.
• EGPA: asthma with eosinophilia. No sinusitis, neuropathy or vasculitic features here, but ANCA could be checked if these develop.
• Post-infectious bronchiolitis obliterans (Swyer-James): hyperlucency after severe infection, typically unilateral. Features are air trapping on expiratory HRCT and fixed obstruction.
• Sarcoidosis and interstitial lung disease: hilar enlargement and reticular opacities. Test with HRCT, DLCO and biopsy if needed.
• Vocal cord dysfunction and GERD-related cough: mimic or worsen asthma. Consider laryngoscopy and a PPI trial.

5. Treatment Plan (GINA-based)

A. Pharmacological

• ICS-formoterol as MART (budesonide-formoterol 160/4.5 µg, or beclometasone-formoterol). Because this patient has daily symptoms and night waking, starting at Step 4 (medium-dose ICS-formoterol maintenance plus as-needed doses) is reasonable.
• ICS reduce eosinophilic airway inflammation and are the core of long-term control. Formoterol is a fast-acting, long-acting β2-agonist (LABA) that also serves as the reliever. Follow the product label for the maximum daily number of inhalations.
• LABA must never be used without ICS in asthma.
• If Track 2 is chosen: ICS-LABA (e.g. budesonide-formoterol, fluticasone-salmeterol) maintenance plus a SABA (salbutamol) as reliever. This is less favored.

• LAMA (tiotropium): bronchodilation through muscarinic blockade, which helps especially with persistent obstruction.
• LTRA (montelukast): blocks cysteinyl leukotrienes. Warn about neuropsychiatric effects.
• Low-dose azithromycin: for refractory cases, with caution.
• Biologics for severe type 2 asthma (after referral to a specialist and confirmation of adherence and technique): anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab, reslizumab), anti-IL-4R (dupilumab), and anti-TSLP (tezepelumab). Eosinophilia makes anti-IL-5 a logical option.

• Oxygen to saturation 93-95% if hypoxemic.
• Repeated SABA (or ICS-formoterol) ± ipratropium.
• Systemic corticosteroids (prednisolone 40-50 mg orally for 5-7 days).
• Antibiotics only for evidence of bacterial infection.

B. Non-pharmacological

• Trigger avoidance: cold air, exertion without warm-up, respiratory infections, allergens, irritants and fumes. Review workplace exposures (perfumes, cleaning agents, dust).
• Smoking and environmental exposure: continue not smoking and avoid passive smoke and air pollution.
• Vaccination: annual influenza, pneumococcal, COVID-19 and RSV where recommended.
• Breathing and physical activity: regular moderate exercise with pre-exercise warm-up and breathing exercises (e.g. diaphragmatic breathing), and pulmonary rehabilitation if there is functional limitation.
• Patient education: a written asthma action plan, recognition of worsening signs, when to use ICS-formoterol or seek urgent care.
• Inhaler technique: demonstrate and check with teach-back at every visit. Use a spacer for metered-dose inhalers.

C. Monitoring and Follow-up

• Review 1-3 months after starting, then every 3-12 months.
• Symptom control: use ACT or ACQ and the four GINA control questions.
• Spirometry: at baseline, 3-6 months after starting treatment, and at least yearly. PEF diary when needed.
• Exacerbations: frequency, oral steroid courses, ER visits.
• Adherence and inhaler technique at every visit.
• Adjust treatment: step up if uncontrolled (after checking technique, adherence, triggers and comorbidities). Consider stepping down after about 3 months of good control.
• Cardiac follow-up of the enlarged heart according to the echo.

6. Final Clinical Conclusion

1. Most likely diagnosis: bronchial asthma, persistent, uncontrolled (probably non-atopic eosinophilic phenotype), complicated by emphysema and possibly pneumosclerosis, with suspected pulmonary hypertension or cardiac involvement not yet proven.
2. Strongest findings:
   • Episodic exertional and nocturnal suffocation, relieved by salbutamol (3-4 times daily).
   • Onset after pneumonia, with attacks triggered by exertion and colds.
   • Diffuse dry rales and wheeze with a bandbox percussion note.
   • Eosinophilia in blood (5%) and sputum (10-12/HPF), with negative M. tuberculosis ×3.
   • Hyperinflation on X-ray (hyperlucent fields, flat low diaphragm).
3. Key confirmatory investigations: spirometry with bronchodilator reversibility, PEF variability, FeNO, total and specific IgE, then HRCT, ECG and echocardiography to clarify the enlarged heart and the